Abstract
Background and Aims: ApoA-1 containing HDL lipoproteins are the major cholesterol acceptors from extra-hepatic tissues. In normal condition, their role in reverse cholesterol transport (RCT) favours lipid homeostasis. Furthermore, they are one of the key effectors in atheroprotection when dyslipidemia occurs and accordingly they have been widely studied1. Nowadays, in vitro reconstituted-HDL (rHDL) can be adequately produced and applied in biomedicine research. Referred to the cardiovascular field, it has been demonstrated that treatments based on rHDL are beneficial both in vitro and in animal studies. However, despite promising, rHDL infusions have failed to reach the prespecified efficacy endpoints when mortality benefit has been tested in clinical trials2. Therefore, with the aim to overcome this handicap, we have set up a methodology to “functionalize” rHDL with a microRNA in order to improve their therapeutic outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
